X4 Pharmaceuticals (NASDAQ:XFOR) & Champions Oncology (NASDAQ:CSBR) Critical Comparison
X4 Pharmaceuticals (NASDAQ:XFOR) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.
Valuation and Earnings
This table compares X4 Pharmaceuticals and Champions Oncology’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|X4 Pharmaceuticals||$3.50 million||46.67||-$43.02 million||N/A||N/A|
|Champions Oncology||$27.07 million||2.31||$130,000.00||$0.01||539.00|
Volatility and Risk
X4 Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
This is a breakdown of current recommendations for X4 Pharmaceuticals and Champions Oncology, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
X4 Pharmaceuticals presently has a consensus target price of $27.00, indicating a potential upside of 105.95%. Champions Oncology has a consensus target price of $13.13, indicating a potential upside of 143.51%. Given Champions Oncology’s higher possible upside, analysts clearly believe Champions Oncology is more favorable than X4 Pharmaceuticals.
Institutional and Insider Ownership
61.2% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.9% of Champions Oncology shares are owned by institutional investors. 4.9% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 44.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares X4 Pharmaceuticals and Champions Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Champions Oncology Company Profile
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.